MaxCyte (MXCT) News Today → [Webinar] A Deep Dive into Options Volatility: Skew & Relative Value (From OIC) (Ad) Free MXCT Stock Alerts GBX 370 +5.00 (+1.37%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineNotice of Annual General Meeting of Vicore Pharma Holding AB (publ)finance.yahoo.com - April 4 at 8:58 AMMaxCyte, Inc. (LON:MXCT) Insider Sells £22,050 in Stockinsidertrades.com - April 3 at 1:17 AMInsider Selling: MaxCyte, Inc. (LON:MXCT) Insider Sells 5,000 Shares of Stockmarketbeat.com - April 2 at 6:06 AMMaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 14 at 9:21 AMMaxCyte's (LON:MXCT) investors will be pleased with their notable 68% return over the last five yearsfinance.yahoo.com - March 13 at 9:33 AMMaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023finance.yahoo.com - March 12 at 7:18 PMMaxCyte earnings: here's what Wall Street expectsmarkets.businessinsider.com - March 11 at 1:19 PMMaxCyte Earnings Previewbenzinga.com - March 11 at 1:19 PMMaxCyte (LON:MXCT) Shares Cross Below Fifty Day Moving Average of $386.32marketbeat.com - February 16 at 5:28 AMMaxCyte Inc Announces Cenk Sumen’s Transition and Severance Termsmsn.com - January 27 at 11:21 AMMaxCyte, Inc.: MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Resultsfinanznachrichten.de - January 9 at 5:54 AMMaxCyte says Q4 revenue is expected to be between $15.5M and $15.7Mmsn.com - January 8 at 5:19 PMMaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Resultsfinance.yahoo.com - January 8 at 5:19 PMMaxCyte and Lion TCR join hands for Lion TCR's global expansionmsn.com - January 3 at 1:00 PMLongtime MaxCyte CEO Doug Doerfler to retire; Maher Masoud tapped as successorbizjournals.com - December 12 at 4:40 PMInsider Sell Alert: President and CEO Douglas Doerfler Sells 25,550 Shares of MaxCyte Inc (MXCT)finance.yahoo.com - December 2 at 9:20 AMMaxCyte May Benefit From Potential Gene Therapy Approvalseekingalpha.com - November 27 at 8:46 AMMaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Memberfinance.yahoo.com - November 16 at 8:52 AMMaxCyte, Inc. (LON:MXCT) Analysts Just Cut Their EPS Forecasts Substantiallyfinance.yahoo.com - November 15 at 12:38 AMMaxCyte, Inc. (NASDAQ:MXCT) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 9 at 3:39 PMMaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidancefinance.yahoo.com - November 8 at 6:11 PMMaxCyte to Participate in Two Upcoming Investor Conferencesfinance.yahoo.com - November 6 at 5:46 PMOne MaxCyte Insider Raised Stake By 400% In Previous Yearfinance.yahoo.com - October 23 at 12:14 PMNeed To Know: The Consensus Just Cut Its MaxCyte, Inc. (LON:MXCT) Estimates For 2023finance.yahoo.com - October 7 at 7:57 AMAfter-hours movers: Clorox falls on Q1 warning, BlackBerry up on split-off plansca.investing.com - October 4 at 11:32 PMMaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidancefinance.yahoo.com - October 4 at 6:32 PMMaxCyte, Inc. (MXCT) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - September 19 at 10:37 AMMaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidancefinance.yahoo.com - August 9 at 8:00 PMMaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patientsfinance.yahoo.com - August 1 at 4:47 PMMaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023finance.yahoo.com - July 13 at 8:23 AMMaxCyte Signs Strategic Platform License With Vittoria Biotherapeuticsmarketwatch.com - July 10 at 9:42 AMMaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapiesfinance.yahoo.com - July 10 at 9:42 AMMaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapiesfinance.yahoo.com - July 10 at 9:42 AMInsider Selling: MaxCyte, Inc. (LON:MXCT) Insider Sells 28,883 Shares of Stockmarketbeat.com - June 16 at 11:17 AMCompanies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growthfinance.yahoo.com - May 30 at 8:51 AMEarnings Working Against MaxCyte, Inc.'s (LON:MXCT) Share Price Following 28% Divefinance.yahoo.com - May 14 at 8:14 AMMaxCyte, Inc. (LON:MXCT) insider upped their holding by 400% earlier this yearfinance.yahoo.com - April 28 at 7:40 AMMaxCyte hires healthcare veteran Swirsky for CFO jobseekingalpha.com - March 27 at 6:17 PMMaxCyte, Inc. (NASDAQ:MXCT) Q4 2022 Earnings Call Transcriptfinance.yahoo.com - March 18 at 9:49 AMMaxCyte, Inc: MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Resultsfinanznachrichten.de - March 16 at 8:13 AMMaxCyte's Earnings: A Previewmsn.com - March 14 at 3:27 PMMaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technologyfinance.yahoo.com - March 8 at 8:04 AMA fantastic week for MaxCyte, Inc.'s (LON:MXCT) 70% institutional owners, one-year returns continue to impressfinance.yahoo.com - January 29 at 7:33 AMMaxCyte, Catamaran Bio Sign Strategic Platform Licensemarketwatch.com - January 4 at 4:43 AMMaxCyte, Inc. (MXCT) Loses 18.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Cornerfinance.yahoo.com - December 21 at 1:28 PMMaxCyte Earnings Perspective: Return On Capital Employedmsn.com - December 14 at 1:48 PMMaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseasesfinance.yahoo.com - December 5 at 3:20 AMInsiders who bought in the last 12 months lose an additional US$55k as MaxCyte, Inc. (LON:MXCT) drops to UK£566mfinance.yahoo.com - November 19 at 3:36 AMMaxCyte, Inc. (MXCT) Q3 2022 Earnings Call Transcriptseekingalpha.com - November 12 at 5:44 PMMaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimatesfinance.yahoo.com - November 9 at 9:50 PM Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address He Is Giving Away Bitcoin (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin. >> Register right here MXCT Media Mentions By Week MXCT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MXCT News Sentiment▼0.000.58▲Average Medical News Sentiment MXCT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MXCT Articles This Week▼00▲MXCT Articles Average Week Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: EKF Diagnostics News Today Creo Medical Group News Today Oxford Biomedica News Today Medica Group News Today Bioventix News Today Tristel News Today Instem News Today hVIVO News Today Arix Bioscience News Today Advanced Medical Solutions Group News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:MXCT) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 Media[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICMissed NVDA? Buy this AI stock NOWChaikin AnalyticsYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
